Renal Failure Clinical Trial
Official title:
Fast-track in Endovascular Aortic Aneurysm Repair With Desflurane and Sevoflurane: a Randomized Clinical Trial
Verified date | November 2023 |
Source | Hospital General Universitario Gregorio Marañon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Randomized Clinical Trial following the evaluation of the impact on renal function in patients undergoing endovascular aortic aneurysm repair with two anesthetics protocols (Desflurane versus Sevoflurane) on the first 24 hours after surgery.
Status | Completed |
Enrollment | 80 |
Est. completion date | March 16, 2021 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - older than 18 years undergoing elective endovascular aortic repair - who have signed informed consent Exclusion Criteria: - urgent surgery - with known hypersensitivity to Desflurane or Sevoflurane. - Renal failure in hemodialysis |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital general universitario Gregorio Marañón | Madrid |
Lead Sponsor | Collaborator |
---|---|
Begoña Quintana Villamandos | Baxter Healthcare Corporation |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Biochemical parameters | NGAL in urine | All these parameters will be evaluated at baseline (presurgery), at the end surgery and 24 hours after surgery in both study groups | |
Primary | Change in Biochemical parameters | Cystatin C(mg/L) in plasma | will be evaluated at baseline (presurgery), at the end surgery and 24 hours after surgery in both study groups | |
Primary | Change in Biochemical parameters | Creatinine(mg/dL) in plasma | will be evaluated at baseline (presurgery), at the end surgery and 24 hours after surgery in both study groups | |
Primary | Change in Biochemical parameters | sodium(mMol/L) in plasma | will be evaluated at baseline (presurgery), at the end surgery and 24 hours after surgery in both study groups | |
Primary | Change in Biochemical parameters | potassium(mMol/L) in plasma | will be evaluated at baseline (presurgery), at the end surgery and 24 hours after surgery in both study groups | |
Primary | Change in Biochemical parameters | Chloride(mMol/L) in plasma | will be evaluated at baseline (presurgery), at the end surgery and 24 hours after surgery in both study groups | |
Primary | Change in Biochemical parameters | albumin(g/dL) in plasma | will be evaluated at baseline (presurgery), at the end surgery and 24 hours after surgery in both study groups | |
Primary | Change in Biochemical parameters | osmolarity(mOsm/Kg) in plasma | will be evaluated at baseline (presurgery), at the end surgery and 24 hours after surgery in both study groups | |
Primary | Change in Biochemical parameters | NGAL in plasma | will be evaluated at baseline (presurgery), at the end surgery and 24 hours after surgery in both study groups | |
Primary | Change in Biochemical parameters | Creatinine(mg/dL) in urine | will be evaluated at baseline (presurgery), at the end surgery and 24 hours after surgery in both study groups | |
Primary | Change in Biochemical parameters | sodium(mMol/L) in urine | will be evaluated at baseline (presurgery), at the end surgery and 24 hours after surgery in both study groups | |
Primary | Change in Biochemical parameters | potassium(mMol/L) in urine | will be evaluated at baseline (presurgery), at the end surgery and 24 hours after surgery in both study groups | |
Primary | Change in Biochemical parameters | Chloride(mMol/L) in urine | will be evaluated at baseline (presurgery), at the end surgery and 24 hours after surgery in both study groups | |
Primary | Change in Biochemical parameters | albumin(g/dL) in urine | will be evaluated at baseline (presurgery), at the end surgery and 24 hours after surgery in both study groups | |
Primary | Change in Biochemical parameters | osmolarity(mOsm/Kg) in urine | will be evaluated at baseline (presurgery), at the end surgery and 24 hours after surgery in both study groups | |
Secondary | Need for postoperative mechanical ventilation | hours of mechanical ventilation in ICU | 24 hours | |
Secondary | ICU length of stay | hours in ICU | up to 24 hours | |
Secondary | anesthetic recovery | time to extubation(minutes). | These variable will be recorded immediately after surgery (from anesthetics discontinuation). The postanesthesia recovery score before will be recorded at baseline and after surgery. time frame upto 1 hour(stimated) | |
Secondary | anesthetic recovery | time to spontaneous eye opening(minutes) | These variable will be recorded immediately after surgery (from anesthetics discontinuation). The postanesthesia recovery score before will be recorded after surgery. timeframe up to 1 hour(stimated). | |
Secondary | anesthetic recovery | time until first response to verbal commands(minutes) | These variable will be recorded immediately after surgery (from anesthetics discontinuation). The postanesthesia recovery score before will be recorded after surgery. timeframe up to 1 hour(stimated). | |
Secondary | anesthetic recovery | The post-anesthesia recovery score ( Modified Aldrete score) (0-1-2 from worse to better) | These variable will be recorded immediately after surgery (from anesthetics discontinuation). The postanesthesia recovery score before will be recorded at baseline and after surgery. timeframe 1 hour(stimated) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02763410 -
Impact of the Composition of Packed Red Blood Cell Supernatant on Renal Dysfunction and Posttransfusion Immunomodulation
|
||
Active, not recruiting |
NCT03183245 -
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
|
Phase 3 | |
Completed |
NCT04084301 -
Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury
|
N/A | |
Completed |
NCT03292029 -
Pilot Medical Evaluation of the T50 Test
|
N/A | |
Suspended |
NCT04589065 -
SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device)
|
N/A | |
Completed |
NCT03806998 -
Effects of a Ketoacid Supplementation in Patients With Stage III to IV Renal Failure
|
Phase 3 | |
Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
Completed |
NCT02325726 -
RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery.
|
N/A | |
Completed |
NCT02116270 -
Accelerated Immunosenescence and Chronic Kidney Disease
|
N/A | |
Completed |
NCT01859273 -
Adherence Enhancement for Renal Transplant Patients
|
N/A | |
Completed |
NCT01388270 -
Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis
|
Phase 4 | |
Completed |
NCT01187953 -
Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacroâ„¢ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx
|
Phase 3 | |
Completed |
NCT00966615 -
The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition
|
Phase 4 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01008631 -
The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy Volunteers
|
N/A | |
Completed |
NCT00737672 -
GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
|
Phase 3 | |
Completed |
NCT00765661 -
Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients
|
Phase 2 | |
Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
Recruiting |
NCT00470769 -
The Efficacy of Color-Doppler Ultrasonography to Assess the Renal Blood Flow With the Estimation of GFR
|
N/A | |
Terminated |
NCT00338455 -
Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
|
Phase 2 |